🇺🇸 FDA
Pipeline program

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

MKKCT-900-002

Phase 3 mab active

Quick answer

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) for Respiratory Syncytial Virus (RSV) is a Phase 3 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Respiratory Syncytial Virus (RSV)
Phase
Phase 3
Modality
mab
Status
active

Clinical trials